Vericel Corporation

VCEL Healthcare Biotechnology

Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024. In the quarter to June 2026, revenue grew 22.5%, EPS grew 500.0% and free cash flow grew 17,503.7%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

40.13 0.89 −2.17%
Market cap
$2.1B
P/E
83.6×
Fwd P/E
76.8×
Dividend yield
—
F-score
7/9
Altman Z
8.21
Beneish M
−2.53
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Total current assets
247.44 212.78 205.63 186.87 158.46 123.56 111.66 112.78 50.51 44.72
Total non-current assets
240.53 219.95 148.03 86.14 85.24 82.05 41.58 5.91 4.07 3.88
Total Assets
487.97 432.72 353.66 273.00 243.71 205.61 153.24 118.69 54.58 48.60
Total current liabilities
49.15 50.29 45.75 37.46 26.05 22.48 19.80 14.79 13.09 12.85
Total non-current liabilities
84.18 90.47 81.96 43.27 47.19 48.87 22.35 1.67 18.95 11.04
Total liabilities
133.33 140.76 127.71 80.73 73.24 71.35 42.15 16.46 32.04 23.89
Common Equity (Total)
354.64 291.97 225.95 192.27 170.46 134.26 111.09 102.23 22.54 (13.68)
Shareholders Equity (Total)
354.64 291.97 225.95 192.27 170.46 134.26 111.09 102.23 22.54 24.71
Total Debt
— — — 47.61 50.18 53.30 27.85 — 17.24 10.10

Show all line items

In millions of $ except per-share values · columns are period end dates